TEST:

Geneseeq’s NGS Liquid Biopsy Kit

National Medical Products Administration (NMPA) announced that Geneseeq’s “EGFR/KRAS/MET Gene Mutation Detection Kit (Reversible Terminator Sequencing Method)” has entered the Special Review and Approval of Innovative Medical Device pathway...The kit uses advanced non-invasive liquid biopsy testing technology to accurately identify tumor-driving mutations by analyzing circulating tumor DNA (ctDNA) in the blood, without the need for tumor tissue samples...This kit is the third NGS IVD product from Geneseeq to enter the NMPA Innovative Medical Device program, following the previous NMPA approvals of the ‘EGFR/ALK/ROS1/BRAF/KRAS/HER2 Mutation Detection Kit‘ and the ‘GeneseeqPrime NGS TMB Testing Kit‘ for tumor tissue testing. From 6 genes to 400+_genes, from tumor tissue to liquid biopsy testing, Geneseeq has always been patient-need driven, continuously exploring the translation of cutting-edge technologies into clinical practice.